GENMAB A/S (GMAB)

Genmab is a publicly traded Danish biopharmaceutical company specializing in the discovery and development of monoclonal antibodies — protein therapeutics engineered to attack specific disease targets. The company (NASDAQ: GMAB) was founded on a distinctive antibody-engineering platform and has grown into a diversified developer of cancer treatments, inflammatory drugs, and other therapies, with a business model split between wholly owned products and revenue-sharing partnerships with larger pharmaceutical partners.

Birth of a platform company: the early vision

Genmab was founded in 1999 by a team of scientists and entrepreneurs in Copenhagen with a singular mission: to create a better way to discover and engineer monoclonal antibodies. At that moment, monoclonal antibodies were already proving their worth in medicine — the first cancer-targeting antibodies were approved or in late-stage testing — but the conventional discovery methods were slow, expensive, and unpredictable. The founding vision was to build a proprietary platform that would accelerate antibody development and stack the odds in favor of success.

The company’s earliest years were lean. Like most early-stage biotech firms, Genmab had no marketed drugs and no near-term revenue. It survived on research grants, government funding, and the belief of early investors that the platform technology would eventually be worth far more than the cost of building it. The founders and early employees took equity rather than high salaries, a gamble that would define the company’s culture and trajectory.

Throughout the early 2000s, Genmab built out its antibody-discovery and engineering capabilities, filing patents on its core platform methods and recruiting experienced cancer biologists and protein engineers. The company also began entering into partnerships with larger pharmaceutical firms — deals that would fund internal research while also generating milestone payments and royalties on any drugs that reached the market. Those partnerships were crucial; they provided cash to sustain operations while keeping the company focused on what it did best: identifying antibody candidates and testing them in the lab.

The pivotal turn: from pure platform to product company

For the first decade, Genmab was almost pure platform — a discovery engine that other companies licensed. But the vision always included the possibility of developing drugs entirely in-house. In 2009, the company took a major step by acquiring Medarex, a fellow antibody specialist, for roughly $650 million. The acquisition was Genmab’s largest bet to date and brought with it several pipeline assets and a track record of clinical development. More importantly, it signaled that Genmab saw itself as an emerging product company, not merely a supplier of technology.

The timing proved prescient. In 2013, Genmab’s tislelizumab (developed in collaboration with Celgene) advanced into clinical trials for lymphoma. In 2014, daratumumab — developed wholly in-house but licensed to Janssen, a subsidiary of Johnson & Johnson — received FDA approval for multiple myeloma, a serious blood cancer. Daratumumab became a blockbuster, eventually achieving annual sales in the billions of dollars. For Genmab, it represented proof of concept: the platform worked, and drugs born from it could succeed in the clinic and the market.

The portfolio takes shape

Over the following decade, Genmab transitioned from a platform-dependent company to a diversified biotech with multiple approved drugs and a deep pipeline. Daratumumab remained the flagship — a major source of cash flow and validation — but it was joined by other approved therapies. In 2019, Genmab received approval for glofitamab for lymphoma, another monoclonal antibody derived from the company’s research. In 2020, Teclistamab, a bispecific antibody (a newer class that binds two targets simultaneously) entered advanced trials and later became approved for myeloma.

The growth of revenue from product sales and milestone payments from partners has been dramatic. Where Genmab once lived almost entirely off grants and royalties, it now combines high-margin royalty streams from licensed drugs with increasing revenue from its own marketed products. This dual model insulates the company from the revenue cliff that a single-drug dependence would create, and it positions Genmab to capture more upside if its own pipeline drugs succeed.

Notably, Genmab has also pursued strategic acquisitions to expand its reach. In 2018, the company acquired AbGenomics for its automated antibody-discovery techniques. In 2021, it acquired Herlev Hospital’s cancer cell-therapy operation in Denmark, broadening its footprint into cell therapies alongside its traditional antibody focus.

How the company makes money now

Genmab’s revenue streams have three main sources. The first is royalties on licensed drugs — most prominently from daratumumab, where Johnson & Johnson pays Genmab a royalty on sales. These are high-margin revenues with minimal incremental cost to Genmab, making them valuable in financial models.

The second is revenue-sharing partnerships where Genmab co-develops a drug with a larger partner (often a major pharmaceutical company) and splits profits or receives milestone payments as the asset progresses through trials and reaches market. These deals reduce Genmab’s risk and capital burden while allowing it to capture a portion of the upside if the drug succeeds.

The third is sales from drugs Genmab markets directly. For therapies like glofitamab and teclistamab that Genmab owns outright, the company captures the full revenue minus the cost of manufacturing, distribution, and marketing. These are typically lower margin than royalties but represent the gross commercial potential without splitting payments.

The company also monetizes its platform through upfront payments and milestone agreements when other biotech or pharma firms license its technology for their own programs — a smaller but steady stream.

Risks and the clinical reality of drug development

Biopharmaceutical companies live with clinical risk. Every drug in Genmab’s pipeline faces the possibility of failure in trials — either because it proves ineffective, because safety signals emerge, or because competitors advance better alternatives. The company’s valuation depends heavily on the success of late-stage candidates; disappointment in any major trial can sharply alter market expectations.

Regulatory risk is equally real. Approval from the FDA or the European Medicines Agency is not guaranteed, even for drugs that have shown promising early data. A clinical hold, a request for additional studies, or an outright rejection can halt progress and consume years and hundreds of millions of dollars.

Competition in monoclonal antibodies and bispecific antibodies has intensified markedly. Genmab is no longer alone in this space; large pharma companies and other biotech firms have built robust antibody-discovery programs. Differentiation increasingly depends on the quality and novelty of the antibody designs and the target selection — getting the right antibody against the right disease at the right moment.

Patent cliffs are another long-term concern. Drugs approved a decade or more ago will eventually lose patent protection, allowing generic (or biosimilar) versions to enter the market at much lower prices. Daratumumab faces this reality; ensuring that newer drugs in the portfolio reach peak sales before patent exclusivity expires is central to long-term value creation.

The evolving business structure

Genmab operates a relatively lean headquarters in Copenhagen and has established operations in the United States (particularly around Boston, a biotech hub) and in select European cities. The company outsources much of the manufacturing of its drugs to contract manufacturers, a common model in modern biotech that keeps fixed costs down and allows flexibility in production volumes.

The company’s workforce is dominated by scientists, clinicians, and regulatory specialists — the human capital that translates the platform into drugs. Retaining talented researchers is a continuous challenge in biotechnology, where competition for top talent is fierce and compensation packages are complex (base salary, bonus, equity, benefits).

How to research Genmab as an investment

Start with the annual 10-K or the equivalent filing (SEC CIK 0001434265) to understand the pipeline composition, the status of late-stage trials, and royalty agreements with partners. The detailed list of pipeline drugs, with their indications and trial phases, is essential context.

Quarterly earnings reports and pipeline updates should be reviewed for any clinical trial results or regulatory actions. Biotech stock prices are often driven by clinical news — a positive trial readout can produce a sharp rally, while a disappointing result can trigger a decline. Understanding the next anticipated milestones (expected trial results, regulatory decisions) and the timeline for them helps frame near-term volatility.

Search for recent clinical trial publications and presentations at medical conferences (like the American Society of Hematology) where Genmab often presents data on its oncology programs. These peer-reviewed or scientifically reviewed presentations offer far more detail than company-issued press releases and provide a window into the strength of efficacy and safety data.

Peer companies like Amgen, Regeneron, and other antibody-focused biotech firms provide context for relative valuation and the stage of maturity of their programs. As with any single security, nothing here constitutes investment advice.